Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Boehringer Ingelheim's Hernexeos (zongertinib) wins FDA accelerated approval for front-line HER2-mutated non-small-cell lung cancer
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, HER2 - Read more

Boehringer Ingelheim, Sitryx Therapeutics partner on autoimmune oral drugs, potentially worth $500M+
Licensing deal, autoimmune, small molecule, milestone payments - Read more

Emergent BioSolutions secures approximately $140M CAD ($102.3M) in Canadian government contracts for medical countermeasures
Government contract, biodefense, manufacturing agreement, medical countermeasures - Read more

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

argenx's Vyvgart (efgartigimod alfa) meets Ph3 primary endpoint for ocular myasthenia gravis treatment
Antibody, autoimmune, antibody fragment, myasthenia gravis, IgG targeting, subcutaneous - Read more

AtaiBeckley's EMP-01 (R-MDMA) shows positive Ph2a results for social anxiety disorder treatment
Small molecule, neurological, MDMA, social anxiety disorder, psychedelic therapy - Read more

SolasCure's Aurase Wound Gel (tarumase) shows faster healing in chronic venous leg ulcers Ph2 trial
Protein therapy, dermatological, enzymatic debridement, chronic venous leg ulcers, tarumase, PAR2 receptors - Read more

Bristol Myers Squibb's iza-bren shows survival benefit in Ph3 trial for triple-negative breast cancer
Antibody drug conjugate, cancer, triple-negative breast cancer, EGFR target, HER3 target - Read more

Eli Lilly's orforglipron (GLP-1) outperforms Novo's Rybelsus in Ph3 diabetes trial on weight loss and blood sugar
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, obesity, oral medication - Read more

MindRank doses first patient in Ph3 trial for MDR-001 oral GLP-1 receptor agonist targeting overweight or obesity
Small molecule, metabolic, GLP-1 receptor agonist, obesity, AI drug design - Read more

Bayer's Xofigo (radium-223 dichloride) plus enzalutamide shows 24% survival benefit in Ph3 metastatic castration-resistant prostate cancer trial
Radiopharmaceutical, cancer, radium-223, metastatic castration-resistant prostate cancer, combination therapy, bone metastases - Read more

Generate Biomedicines raises $400M IPO, AI drug discovery specialist developing asthma treatments
AI/ML platform, drug discovery, autoimmune, clinical-stage - Read more

Metagen Therapeutics raises ¥3.52B ($22.5M) Series B for microbiota drug development
Microbiota therapeutics, ulcerative colitis, fecal microbiota transplantation, clinical-stage - Read more

Asahi Kasei acquires Germany's Aicuris for $920M to boost viral infection R&D portfolio
Antiviral, infectious disease, strategic, major transaction - Read more

Walgreens launches Weight Management GLP-1 programme with virtual healthcare platform
GLP-1 receptor agonist, obesity, strategic, operational - Read more

Protagonist Therapeutics plans to opt out of Takeda rusfertide profit-sharing for $400M payments
Licensing deal, rare disease, small molecule, milestone payments, royalties - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Viatris to cut 10% of workforce in 3-year restructuring, reports fire at India manufacturing plant
Generic drugs, operational, cost reduction, financial - Read more

Senate hearing criticizes FDA's rare disease review process following Biohaven's troriluzole rejection for spinocerebellar ataxia
Small molecule, neurological, regulatory, rare disease - Read more

CDC vaccine panel schedules March meeting to discuss COVID-19 vaccine safety and long COVID issues
mRNA vaccine, infectious disease, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here